<SEC-DOCUMENT>0001714899-21-000050.txt : 20210503
<SEC-HEADER>0001714899-21-000050.hdr.sgml : 20210503
<ACCEPTANCE-DATETIME>20210503083435
ACCESSION NUMBER:		0001714899-21-000050
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210503
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210503
DATE AS OF CHANGE:		20210503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Denali Therapeutics Inc.
		CENTRAL INDEX KEY:			0001714899
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				463872213
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38311
		FILM NUMBER:		21881525

	BUSINESS ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 866-8548

	MAIL ADDRESS:	
		STREET 1:		161 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dnli-20210503.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:67016832-7f88-47df-970a-7eabb3dddae6,g:2c3b9b23-c749-495f-b243-f16d76649285,d:df95d7da71b3433cad3a0702ac050c36--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>dnli-20210503</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl80L2ZyYWc6MzUwM2E0MjY0ZTNjNDRmYTg5MGUyYmM2MDEwMzliNjUvdGFibGU6MzMwYTM0NzJiY2NiNDllZGJmNWQ2YjRmOWUwOTEzOGIvdGFibGVyYW5nZTozMzBhMzQ3MmJjY2I0OWVkYmY1ZDZiNGY5ZTA5MTM4Yl8yLTEtMS0xLTA_525d213b-4b67-412b-b512-a4e44a9f8408">0001714899</ix:nonNumeric><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl80L2ZyYWc6MzUwM2E0MjY0ZTNjNDRmYTg5MGUyYmM2MDEwMzliNjUvdGFibGU6MzMwYTM0NzJiY2NiNDllZGJmNWQ2YjRmOWUwOTEzOGIvdGFibGVyYW5nZTozMzBhMzQ3MmJjY2I0OWVkYmY1ZDZiNGY5ZTA5MTM4Yl8zLTEtMS0xLTA_23b2d1e3-de1e-4195-8db5-cf87d2104dee">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="dnli-20210503.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001714899</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-03</xbrli:startDate><xbrli:endDate>2021-05-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idf95d7da71b3433cad3a0702ac050c36_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV85NDQ_0a1f1af9-8e72-48d4-ab82-f610c92610f5">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): </span></div><div style="margin-bottom:2pt;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8yMzI_94f65d02-1fc2-4d13-b717-72960a380757">May&#160;3, 2021</ix:nonNumeric></span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8yMzc_eba6ec90-48e1-4ac3-94b8-ed9dcfd5e3b8">Denali Therapeutics Inc.</ix:nonNumeric></span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6MGJjMWY0ZDFlYzBkNDI2MmI3OWRlMWQwZDA3NmQ2Y2EvdGFibGVyYW5nZTowYmMxZjRkMWVjMGQ0MjYyYjc5ZGUxZDBkMDc2ZDZjYV8wLTAtMS0xLTA_4ca3dfb4-8f3e-4d8a-84d1-10e35c0cca33">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6MGJjMWY0ZDFlYzBkNDI2MmI3OWRlMWQwZDA3NmQ2Y2EvdGFibGVyYW5nZTowYmMxZjRkMWVjMGQ0MjYyYjc5ZGUxZDBkMDc2ZDZjYV8wLTItMS0xLTA_dea94927-7414-4218-aa69-d0d098bcfab8">001-38311</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6MGJjMWY0ZDFlYzBkNDI2MmI3OWRlMWQwZDA3NmQ2Y2EvdGFibGVyYW5nZTowYmMxZjRkMWVjMGQ0MjYyYjc5ZGUxZDBkMDc2ZDZjYV8wLTQtMS0xLTA_56c4dabf-3853-4e3d-98e8-2335ae832d0e">46-3872213</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8zMDA_bdb26f0b-d797-46c1-8e96-cd4616f191c0">161 Oyster Point Blvd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8zMDM_929902c5-e3f8-4cd2-8195-ed8fce1e9f4f">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8zMDc_2e3d6f15-faab-41c9-9e2f-bd9eb5a6d589">California</ix:nonNumeric> <ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8zMTA_e17877be-bd6f-418e-9cce-2003e839bc63">94080</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8zNzg_bd8e12ef-89f3-45be-acfd-787d7ec8131e">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8zODI_9cf5dea2-9097-4b5d-b28f-44ef8a8695cb">866-8548</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="margin-bottom:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last reports)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.415%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6YTBlYmUxMTRhYTM4NGFmZGJjNmRhYWU0MjEzNDU4ZTQvdGFibGVyYW5nZTphMGViZTExNGFhMzg0YWZkYmM2ZGFhZTQyMTM0NThlNF8wLTAtMS0xLTA_7be14301-67b2-418f-bf74-b236a07e550b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6YTBlYmUxMTRhYTM4NGFmZGJjNmRhYWU0MjEzNDU4ZTQvdGFibGVyYW5nZTphMGViZTExNGFhMzg0YWZkYmM2ZGFhZTQyMTM0NThlNF8xLTAtMS0xLTA_5c4f7ec2-0a48-443d-8b39-55e9ebc600bc">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6YTBlYmUxMTRhYTM4NGFmZGJjNmRhYWU0MjEzNDU4ZTQvdGFibGVyYW5nZTphMGViZTExNGFhMzg0YWZkYmM2ZGFhZTQyMTM0NThlNF8yLTAtMS0xLTA_20d17709-d67c-42f7-b885-f48e01f7350e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6YTBlYmUxMTRhYTM4NGFmZGJjNmRhYWU0MjEzNDU4ZTQvdGFibGVyYW5nZTphMGViZTExNGFhMzg0YWZkYmM2ZGFhZTQyMTM0NThlNF8zLTAtMS0xLTA_03b408e1-97a8-44c7-948d-11b29a35aa31">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company  </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6NTc5NWFjMTIwY2EzNDhmZGJlNzYxNmIyMDIyMDYwZTkvdGFibGVyYW5nZTo1Nzk1YWMxMjBjYTM0OGZkYmU3NjE2YjIwMjIwNjBlOV8wLTEtMS0xLTA_cf800afe-44f7-4bba-9426-2047327dfad9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></div></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6ODg1ZDMzYWY5ZGE5NGIyNWJjMzk4YmMzZTQ1ZTFkYWYvdGFibGVyYW5nZTo4ODVkMzNhZjlkYTk0YjI1YmMzOThiYzNlNDVlMWRhZl8xLTAtMS0xLTA_497e423c-05ab-43fb-91c8-63dc61e73df1">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6ODg1ZDMzYWY5ZGE5NGIyNWJjMzk4YmMzZTQ1ZTFkYWYvdGFibGVyYW5nZTo4ODVkMzNhZjlkYTk0YjI1YmMzOThiYzNlNDVlMWRhZl8xLTEtMS0xLTA_a10543a0-6aa6-4b70-8fd9-5b0e3d669406">DNLI</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6ODg1ZDMzYWY5ZGE5NGIyNWJjMzk4YmMzZTQ1ZTFkYWYvdGFibGVyYW5nZTo4ODVkMzNhZjlkYTk0YjI1YmMzOThiYzNlNDVlMWRhZl8xLTItMS0xLTA_770d84bd-97da-4179-bfb4-28b215f00238">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.639%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idf95d7da71b3433cad3a0702ac050c36_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 &#160;&#160;&#160;&#160;Results of Operations and Financial Condition. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;3, 2021, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2021. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit&#160;99.1) shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.</span></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)  Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.789%"><tr><td style="width:1.0%"></td><td style="width:11.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991pressreleaseq12021.htm">Press Release dated </a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991pressreleaseq12021.htm">May</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991pressreleaseq12021.htm"> </a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991pressreleaseq12021.htm">3</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991pressreleaseq12021.htm">, 2021</a>.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL)</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idf95d7da71b3433cad3a0702ac050c36_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:justify;text-indent:37pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENALI THERAPEUTICS INC.</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 3, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Steve E. Krognes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steve E. Krognes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Treasurer</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991pressreleaseq12021.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib01f9207df8d434b963cdb790959bf0c_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">99.1</font></div></div><div><img alt="denali_txlogox011a.jpg" src="denali_txlogox011a.jpg" style="height:61px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SOUTH SAN FRANCISCO &#8211; May&#160;3, 2021 &#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Denali Therapeutics Inc. (NASDAQ&#58; DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2021, and provided business highlights.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Our programs have reached a number of exciting milestones so far this year across our broad portfolio of targeted therapeutics for neurodegenerative diseases,&#8221; said Ryan Watts, Ph.D., Denali&#8217;s Chief Executive Officer. &#8220;We remain focused on advancing our lead clinical programs including DNL310 for Hunter syndrome, DNL151 (BIIB122) in collaboration with Biogen for Parkinson's disease, and DNL343 for amyotrophic lateral sclerosis (ALS). In addition, based on human biomarker proof of concept achieved with DNL310, we see significant potential in using our Transport Vehicle (TV) technology to create new, effective biologic therapeutics previously not possible due to limitations posed by the blood-brain barrier, and we continue to rigorously advance additional TV-enabled programs towards the clinic.&#34;    </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Business Highlights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Achieved clinical and regulatory milestones with DNL310&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Denali reported three-month data from Cohort A (n&#61;5) in a Phase 1&#47;2 study of DNL310, Denali&#8217;s lead TV-enabled brain-penetrant enzyme replacement therapy, in patients with Hunter syndrome (MPS II). The data showed that DNL310 treatment resulted in normalization of glycosaminoglycan (GAG) levels in cerebrospinal fluid and a safety and tolerability profile consistent with standard of care enzyme replacement therapy. In March 2021, Denali announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to DNL310 for the treatment of patients with Hunter syndrome. Denali plans to report six-month data from Cohort A in mid-2021 at a medical conference. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Met safety and biomarker goals in DNL151 (BIIB122) Phase 1&#47;1b studies&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In May 2021, Denali presented results from two studies of its small molecule LRRK2 inhibitor, DNL151 (BIIB122), a Phase 1 study in healthy volunteers and a Phase 1b study in patients with Parkinson's disease, at the International Association of Parkinsonism and Related Disorders Virtual Congress held on May 1-4. DNL151 (BIIB122) was generally well tolerated, and target engagement and pathway engagement biomarker goals were met. Denali and Biogen plan to initiate late-stage clinical development of DNL151 (BIIB122) in patients with Parkinson's disease by year-end 2021. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Met safety and pathway engagement biomarker goals in DNL343 Phase 1 healthy volunteer study&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on interim data from the ongoing Phase 1 single- and multiple-ascending-dose study of Denali&#8217;s small molecule EIF2B activator, DNL343, in healthy volunteers, safety and pathway engagement biomarker goals of the study were met. A maximum tolerated dose was not reached, and an additional multiple dose cohort has been added to the study to further explore the therapeutic window. Based on these data, Denali plans to initiate a Phase 1b study in patients with ALS in the second half of 2021. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DNL758 (SAR443122) advancing into Phase 2 study for cutaneous lupus erythematosus (CLE)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Denali announced its partner Sanofi's decision, upon completion of a Phase 1b study in hospitalized adult patients with severe COVID-19 lung disease, to cease further development of DNL758 (SAR443122), a peripherally-restricted small molecule inhibitor of RIPK1, in COVID-19 based on the rapidly evolving landscape of treatment and prevention options for COVID-19. Although the Phase 1b study did not meet its primary endpoint, DNL758 (SAR443122) was generally well tolerated and did generate positive signals of relevant biological effect. Sanofi plans to commence dosing in a Phase 2 study of DNL758 (SAR443122) in CLE patients in the first half of 2021. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary Table of Upcoming 2021 Expected Key Milestones</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Timing</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investigational Drug Candidate</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Therapeutic Area</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Milestone</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1H 2021</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RIPK1 inhibitor (DNL758&#47;SAR443122)</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CLE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commence dosing in Phase 2 study in CLE patients (Sanofi)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mid 2021</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ETV&#58;IDS (DNL310)</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hunter syndrome (MPS II)</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6-month data from Cohort A of Phase 1&#47;2 study</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2H 2021</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EIF2B activator (DNL343)</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALS, FTD</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiate Phase 1b study in ALS patients</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2H 2021</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RIPK1 inhibitor (DNL788&#47;SAR443820)</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALS, Alzheimer&#8217;s disease, MS</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phase 1 data in healthy volunteers (Sanofi)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Late 2021</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LRRK2 inhibitor (DNL151&#47;BIIB122)</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parkinson&#8217;s disease</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initiate late-stage clinical development in Parkinson's patients</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Late 2021</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PTV&#58;PGRN (DNL593)</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FTD</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">File IND application or CTA</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Late 2021&#47;Early 2022</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATV&#58;TREM2 (DNL919)</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alzheimer&#8217;s disease</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">File IND application or CTA</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Participation in Upcoming Investor Conferences</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Members of Denali&#8217;s management will participate in the following upcoming investor conferences&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">UBS Global Healthcare Virtual Conference, May 24-26</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jefferies Healthcare Conference, June 1-3</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Goldman Sachs 42nd Annual Global Healthcare Conference, June 8-10</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">2021 Wedbush PacGrow Healthcare Conference, August 10-11</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter 2021 Financial Results</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ended</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Denali reported a net loss of $70.0 million compared with a net loss of $56.8&#160;million for the three months</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ended</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2020</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $7.9 million for the three months ended </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, compared to $3.6&#160;million for the three months ended </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2020</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase of $4.3&#160;million in collaboration revenue was primarily due to an increase in revenue from our collaboration with Takeda driven by increased costs incurred in the underlying partnered programs.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses were </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.2 million</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three months ended </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$51.0&#160;million</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three months ended</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March 31, 2020. The increase of approximately </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.2&#160;million </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was primarily attributable to an increase in personnel-related expenses, including stock-based compensation, driven primarily by higher headcount and additional equity award grants at a higher market price. Additionally, there were increases in external expenses related to progression of Denali's portfolio, including costs related to the progress of the EIF2B and ETV&#58;IDS programs in the clinic in 2021. Other increases included TV platform and other program external expenses reflecting the increased investment in Denali's pipeline. These increases were partially offset by a decrease in the LRRK2 program external expenses primarily due to completion of the Phase 1 and 1b studies, as well as cost sharing reimbursements from Biogen under the Biogen collaboration agreement, and a decrease in other external research and development expenses.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$18.9 million</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three months ended March 31, 2021, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.6&#160;million </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three months ended </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2020</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of approximately </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.3 million</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was primarily attributable to an increase in personnel-related expenses, including stock-based compensation, driven primarily by higher headcount and additional equity award grants at a higher market price. Additionally, there were increases in legal and other professional services expenses, including accounting and tax expenses associated with assessing the Biogen collaboration agreement, and other general costs such as insurance, tax and IT related expenses.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities were </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.45 billion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Denali Therapeutics</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For additional information, please</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> visit www.denalitherapeutics.com.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali's progress, business plans, business strategy, product candidates, planned preclinical studies and clinical trials and expected milestones&#59; plans to conduct clinical development activities across various programs&#59; plans, timelines and expectations related to DNL310 and Denali&#8217;s TV technology&#59; plans, timelines and expectations related to DNL151 of both Denali and Biogen, including with respect to initiation of late-stage clinical development&#59; plans, timelines and expectations related to DNL343, including with respect to the initiation of future clinical trials&#59; plans, timelines and expectations related to DNL788 and DNL758 of both Denali and Sanofi, including with respect to the availability of data and the initiation of future clinical trials&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali&#8217;s expectations regarding DNL593 and DNL919 and plans and expectations regarding planned regulatory filings&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denali&#8217;s priorities, regulatory approvals, timing and likelihood of success and expectations regarding collaborations&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and statements made by Denali&#8217;s Chief Executive Officer. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to, risks related to&#58; any and all risks to Denali&#8217;s business and operations caused directly or indirectly by the evolving COVID-19 pandemic&#59; risk of the occurrence of any event, change or other circumstance that could give rise to the termination of Denali&#8217;s agreements with Sanofi, Takeda, Biogen or any of Denali&#8217;s other collaboration agreements&#59; Denali&#8217;s early stages of clinical drug development&#59; Denali&#8217;s and its partners&#8217; ability to complete the development and, if approved, commercialization of its product candidates&#59; Denali&#8217;s and its partners&#8217; ability to enroll patients in its ongoing and future clinical trials&#59; Denali&#8217;s reliance on third parties for the manufacture and supply of its product candidates for clinical trials&#59; Denali&#8217;s dependence on successful development of its blood-brain barrier platform technology and its current programs and product candidates&#59; Denali&#8217;s and its partners' ability to conduct or complete clinical trials on expected timelines&#59; the risk that preclinical profiles of Denali&#8217;s product candidates may not translate in clinical trials&#59; the potential for clinical trials to differ from preclinical, early clinical, preliminary or expected results&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the risk of significant adverse events, toxicities or other undesirable side effects&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the uncertainty that product candidates will receive regulatory approval necessary to be commercialized&#59; Denali&#8217;s ability to continue to create a pipeline of product candidates or develop commercially successful products&#59; Denali&#8217;s ability to obtain, maintain, or protect intellectual property rights related to its product candidates&#59; implementation of Denali&#8217;s strategic plans for its business, product candidates and blood-brain barrier platform technology&#59; and other risks, including those described in Denali&#8217;s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2021 and Denali&#8217;s future reports to be filed with the SEC. The forward-looking statements in this press release are based on information available to Denali as of the date hereof. Denali disclaims any obligation to update any forward-looking statements, except as required by law.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="ib01f9207df8d434b963cdb790959bf0c_4"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.215%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue from customers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,922&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,552&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other collaboration revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total collaboration revenue</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,923&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,604&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,207&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,016&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,936&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,555&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,143&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,571&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(71,220)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59,967)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,179&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,069&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70,041)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,898)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70,041)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,763)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.58)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.55)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,884,665</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102,419,718</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________</font></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%;padding-left:10.69pt">Includes related party collaboration revenue from customer of $0.9 million for the three months ended March 31, 2021.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%;padding-left:10.69pt">Includes an offset to expense from related party cost reimbursement of $2.5 million for the three months ended March 31, 2021.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="ib01f9207df8d434b963cdb790959bf0c_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435,321&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">507,144&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977,827&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">962,553&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost sharing reimbursements due from related party</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,511&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,674&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,963&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,284&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431,622&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,495,655&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term marketable securities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,885&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,699&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,376&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,846&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,236&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,618&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,739&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,462&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,547,858&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,604,280&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity </font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,626&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,071&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,963&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,503&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,049&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,497&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued manufacturing costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,342&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,140&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accruals and other current liabilities </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,299&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,315&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liability, current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,876&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,690&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Related party contract liability, current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,569&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,569&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities, current</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,886&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,914&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,610&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,699&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Related party contract liability, less current portion</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292,956&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293,849&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities, less current portion</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,322&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,325&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liability, less current portion</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,916&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,175&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">701&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">701&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">442,505&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">453,749&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,105,353&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150,531&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,547,858&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,604,280&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Relations Contact&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laura Hansen, Ph.D.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President, Investor Relations</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(650) 452-2747</font></div><div><font style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">hansen&#64;dnli.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Media Contacts&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lizzie Hyland</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(646) 495-2706</font></div><div><font style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">lizzie.hyland&#64;fgh.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Morgan Warners</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202) 295-0124</font></div><div><font style="color:#3051f2;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">morgan.warners&#64;fgh.com</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>dnli-20210503.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67016832-7f88-47df-970a-7eabb3dddae6,g:2c3b9b23-c749-495f-b243-f16d76649285-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dnli="http://www.denalitherapeutics.com/20210503" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.denalitherapeutics.com/20210503">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20210503_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20210503_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20210503_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dnli-20210503_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.denalitherapeutics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>dnli-20210503_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67016832-7f88-47df-970a-7eabb3dddae6,g:2c3b9b23-c749-495f-b243-f16d76649285-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/Cover" xlink:type="simple" xlink:href="dnli-20210503.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.denalitherapeutics.com/role/Cover" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>dnli-20210503_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67016832-7f88-47df-970a-7eabb3dddae6,g:2c3b9b23-c749-495f-b243-f16d76649285-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/Cover" xlink:type="simple" xlink:href="dnli-20210503.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.denalitherapeutics.com/role/Cover" xlink:type="extended" id="i5fe46e1ee35441d6b39ab6b935a1144a_Cover"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>dnli-20210503_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67016832-7f88-47df-970a-7eabb3dddae6,g:2c3b9b23-c749-495f-b243-f16d76649285-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_93bb31c9-c97c-4ebb-b90f-f58d5af1368d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5e252b23-2728-43f0-b8d3-522b1e4af8a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2745ae09-1e5b-4d42-9455-2e59b67d5474_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d17a2e98-dc05-42dd-9522-f79b38fe102c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_26576b35-fc34-4743-ac3d-39f23677ede3_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4c30ba96-57b6-454b-847c-e1c9aa79d8c0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e24f1791-da24-4e61-9b33-545af6ef1e14_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2e4b51a8-54bd-415e-b07b-5c0bf3f2328b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_33d0fbed-40e7-40fa-a9f0-4d9f67d4c3d9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_47ba5f0e-4e7c-4dfe-9298-b04cc3489b07_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c9270d39-5138-4601-a6f4-030142bfe55c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_62719650-bbb4-4c9e-bd4a-21d8116a1fc7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1b7e0821-0f71-48d6-bf47-7c0f2b3afae7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_0eb4eb29-99e1-495a-9f03-9ca82568eab3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_b2fd4a1f-cfba-4346-b7af-321a6b91ffc6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d9cae37a-1071-4184-a539-e970c925c260_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a69f6164-d002-413a-91cc-1bcfc7549355_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6d6dbfc8-c0a2-4ed3-b33a-8fedcb8ec7ca_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8ea09280-08a6-4a11-96e8-1f98cbe1569d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_67a0589f-dd31-473b-8c84-4c53a0bd7521_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_dd9bf944-b644-4bb8-8bc7-c958628216ef_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_253fff40-9e2e-4c63-8fea-e8c0f957bf06_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>dnli-20210503_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:67016832-7f88-47df-970a-7eabb3dddae6,g:2c3b9b23-c749-495f-b243-f16d76649285-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.denalitherapeutics.com/role/Cover" xlink:type="simple" xlink:href="dnli-20210503.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.denalitherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3676ba25-0dcb-456d-aca8-4c3c9da183f2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_DocumentType_3676ba25-0dcb-456d-aca8-4c3c9da183f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6b072738-805b-4ac3-b4e7-e2cc1f9ccdc6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_DocumentPeriodEndDate_6b072738-805b-4ac3-b4e7-e2cc1f9ccdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9da069dc-9af3-4e4a-b09f-cc9495c794b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_EntityRegistrantName_9da069dc-9af3-4e4a-b09f-cc9495c794b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_54ad2b8e-d740-4052-bfaf-fe15006c2936" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_54ad2b8e-d740-4052-bfaf-fe15006c2936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9dad89f2-3a77-4316-87a6-13ee87aa554a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_EntityFileNumber_9dad89f2-3a77-4316-87a6-13ee87aa554a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1830d82a-b61a-4620-9d6a-f1c76871134c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_EntityTaxIdentificationNumber_1830d82a-b61a-4620-9d6a-f1c76871134c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f022cd03-477e-43dd-9b55-5cf639442c1d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_EntityAddressAddressLine1_f022cd03-477e-43dd-9b55-5cf639442c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_07f441ca-679e-4000-bd98-19aebff6e8f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_EntityAddressCityOrTown_07f441ca-679e-4000-bd98-19aebff6e8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0eb4c0f9-4b04-4633-8aa4-df3a6ee3c6c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_EntityAddressStateOrProvince_0eb4c0f9-4b04-4633-8aa4-df3a6ee3c6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_68904d37-5f2e-439f-895e-3c9daef8c64a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_EntityAddressPostalZipCode_68904d37-5f2e-439f-895e-3c9daef8c64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_13db7e89-1b58-47a3-a334-97e3e2f40aab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_CityAreaCode_13db7e89-1b58-47a3-a334-97e3e2f40aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_7848a13f-dea6-442a-a351-14e6888648dc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_WrittenCommunications_7848a13f-dea6-442a-a351-14e6888648dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2d476341-22b1-4769-a289-e9cc8cce63da" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_LocalPhoneNumber_2d476341-22b1-4769-a289-e9cc8cce63da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_17098280-3bee-4e6f-b852-5e91e0fd6f37" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_SolicitingMaterial_17098280-3bee-4e6f-b852-5e91e0fd6f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_cf340c50-bb0f-4ab4-bd54-62c2a15d14d5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_PreCommencementTenderOffer_cf340c50-bb0f-4ab4-bd54-62c2a15d14d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d8d72d87-343d-44fb-b29b-38bfde52e445" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d8d72d87-343d-44fb-b29b-38bfde52e445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2d3b8520-e381-4df1-ac8d-ef1a87f33129" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_EntityEmergingGrowthCompany_2d3b8520-e381-4df1-ac8d-ef1a87f33129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b1be5cf4-52fe-4925-9052-a9ae5fa9c602" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_Security12bTitle_b1be5cf4-52fe-4925-9052-a9ae5fa9c602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_eed58482-6c24-4f12-a51d-a8b033a24548" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_TradingSymbol_eed58482-6c24-4f12-a51d-a8b033a24548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_126870b6-cd61-48ad-b762-5174b09a423e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_SecurityExchangeName_126870b6-cd61-48ad-b762-5174b09a423e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ed36d907-f3d9-4ab3-bf60-79995ada75c7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_EntityCentralIndexKey_ed36d907-f3d9-4ab3-bf60-79995ada75c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f1d57cf6-8295-47ce-9fd6-276e0fc2080a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_963720f6-dcaf-4f89-97c9-2ee9ae1eaef3" xlink:to="loc_dei_AmendmentFlag_f1d57cf6-8295-47ce-9fd6-276e0fc2080a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>denali_txlogox011a.jpg
<TEXT>
begin 644 denali_txlogox011a.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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MQ #7  $  @,! 0$! 0          "0H%!P@&! ,! @$!  (# 0$! 0
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M4HT]:^[KTD@D(1:X\=<==(X^V5+ERVRVF9GH]D-&CHY
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M%HUK.L,R,,@                #G#>OFJV?V+2N'E%XNVRC@2IK#<:2Q9Y
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M,UTU:UF2&VWRB27EGHAE0BY-O>G3'35-Q[G'DZ.%OI=EC@D
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ME'"4B%*)"E192$DW(01]"7$.-MUN3';';2>"VQ9:Y:\U>/MCJ;M'-T
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MQ=2MS[J;?EQ]%>M&4I2EJ4M:C4I1FI2E&:E*4H]34HSU,S,SZ3$I"?P
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M2ETS,]3*P(B+A1T0=U32T7CA*RV>36LXYXQP2A"(F@
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M+3FC';PTF7,__P#K7_\ Z*_B6.O_ */_ (?N</\ U_\ Q_>YU'1Q
M                 &T-G]W,NV4SBKSC$)BFI4-Q+5G6...)KL@IUN(7-I;5
MI!Z.Q):4%HK3C9=)+K9DXA)EK>E<E>6SICR6QVYJK*6U6YF-[OX'09_BKYN5
MEW&XW(KJD',JK%A1LV-18(09DW,KY25(5_JK3PN(U0M*CJKTFEIK/%<4O&2L
M7KPEL,:MP           $1?/YS4/(>L=A=OK$VD)03&Y5W"=,EK4LD.>\R'(
M;,C0A*-#LS0?IN+LJC(BDMG-VV'_ -2W=^*!NL__ *5._P##\41PF*\
M                  !/[W=OV;:SXWY7ZJCBNW/F]RVVGDQVR[H$=)
M    !"7SY\TS^9W=ALK@EB:<.Q^8<?-+**LN')\A@R"-=2TZ1<:J6@E,Z*,E
M$F3+2H]#0TTM<_;X>6/>6\4\%;NL_-/NZ^&./THSA*0@
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M6=;.CJXX\VOGQVY4.6PO0N)F1'=2M)^BDR%3,3$Z3Q743$QK'!]XPR
M            "-+O/?HEV_\ .*CYM7HE;3QSV(6]\N.U".)ZM    =_=VW]H
M:;YNLE]T\=$?=>5WI>S\[NE/.*Y:                               B
M,[U#]A/[S_X>";L_U=WWH&^_3W_<B-$Q7@   )1.Z\_/W='XH4_NRH1-WX8[
M4[9>*W8FA$%8@  _PXVV\VMIU"'6G4*;=:<2E;;C:TFE:%H41I6A:3,C(RT,
M@'YQXT:(TEB)'8BL)-1I9CM-LM)-1FI1I;;2E!&I1ZGT=)@/\)A0TRES4Q(J
M9KB20Y+2PT4IQ!)0DD+D$CK5))+:2T,]-$E]P-?8:1Q]K_;<6*T\](:C,-R)
M'#VA]MEM#S_ 6B.N=2DEN\!=!<1GH ^/Q+3==VCQ36=HZSKNO[!%Z[KN+CZW
MK>JX^LX^GBUUUZ1G66-(5+1<*$                          $AW=Y;W.
M8+N8YMA=33;Q;<IQ#-<AY9$Q7YNPVE%4\CBUX#OHS9P5$DN)U\XNIZ($;<X^
M:G/'&/L3-IEY;\D^&WVIUQ7K,          '/W,[O(UL;L_D>9,K9/()"48_
MA\=XB6F1D]LV\F$XIL]$O,U<9EZ:Z@S+K&HRDD9&HATQ4]Y>*^SVN6;)[K'-
MO;[.U6DFS9=E,EV,^2],G3Y+\V;,DN*>D2I<IU;\F3(>69K=>?>6I2U&9FI1
MF9BU4TSK.L\7S P                        G][NW[-M9\;\K]51Q7;GS
M>Y;;3R8[9=T".D@        #D7G1WQ>V4V?FN4DHXV:9J\[C&+.M.$B37==&
M6Y<9 UT<1'403X6U%THER&#/HU';!C]Y?I\,(^YR^[Q]'BGHA75,S,S,S,S,
MS,S,]3,S\)F?HF8LU0_@                           )]^07?!S=#:@\
M/O9IR<OVR.)3/./N&J598L^VLL<L5J6?$\[$1'<A.F6ID4=M:SXG>FNW./DO
MS1X96NUR\^/EGQ5^QW<(Z4                         (L^\JV;.UQS'M
MZJ>(DYF,*:QG,%M(_".T-E++Q!8O*+1/!5W4A<8SZ5J[>W_JM]$O:WTF<<^W
M@@[S'K$9(]G1*&83E<     )T.[HWB]^>V$_;*VDDN]VT>059UCFK\S$+9Y]
MZ :26?&[XFL">C*-/I6F%1D]&I:U^ZIRWYXX3]JTV>3FIR3QK]B141DL
M              $:7>>_1+M_YQ4?-J]$K:>.>Q"WOEQVH1Q/5H   #O[NV_M
M#3?-UDONGCHC[KRN]+V?G=TIYQ7+0                              $
M1G>H?L)_>?\ P\$W9_J[OO0-]^GO^Y$:)BO    2B=UY^?NZ/Q0I_=E0B;OP
MQVIVR\5NQ-"(*Q         %7[?'9/+]C<XM,5R6NF)KTS)2L:R!3"_%N1TQ
M.<4.="EI049R1V9:.TLI/CCO&:%$6A:VV/)7)7FA2Y<5L5N6W#V--C=R
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MOOT]_P!R(T3%>    E$[KS\_=T?BA3^[*A$W?ACM3MEXK=B:$05B
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M2R:EPGE,N&TZGTC\=WAXVG$ZH<;4E23-)D8L8F+1S1PE56K-;36W&'GQEJ
M  G_ .[OR-V]Y;ZVO=<ZSWI9;E&.-ZF9J0TZ]%R9#:C,S,^ LC]+X-$:$700
MKMS&F77KA;;2=<.G5,_B[F$=)         %8[F;R1W+.8+=^X=<-XO?W>U$9
MT^+T\#')2L<K3+C,U$GQ?5-:$>FA>@7@%MBC3'6/H4N>W-EM/T_9T-%C=R
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MCI4F/;5T&R82K7B2S.C-2FDJU2D^(D.EKT%_H%/,:3HO8G6-61&&0
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M0M[Y<=J$<3U:    [^[MO[0TWS=9+[IXZ(^Z\KO2]GYW=*><5RT
M                     !$9WJ'["?WG_P /!-V?ZN[[T#??I[_N1&B8KP
M $HG=>?G[NC\4*?W94(F[\,=J=LO%;L30B"L0
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M/&M1-(326C;$E:S+B)A#J4Z<9CEGI[S',>V.F'?;Y/=Y(F?#/1*R(*M<
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M\95!MDXZKI<E,O\ AT%9GIR9.CA/2M]MD]YBC7Q1T.NQQ2
M  $:7>>_1+M_YQ4?-J]$K:>.>Q"WOEQVH1Q/5H   #O[NV_M#3?-UDONGCHC
M[KRN]+V?G=TIYQ7+0                              $1G>H?L)_>?\
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M]1/#,<6+<)[%3$7"A     %L['O8"C]J*WU$R*>>*^KPCL9<89
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MIXY[$+>^7':A'$]6@   ._N[;^T--\W62^Z>.B/NO*[TO9^=W2GG%<M
M                          1&=ZA^PG]Y_P##P3=G^KN^] WWZ>_[D1HF
M*\   !*)W7GY^[H_%"G]V5")N_#':G;+Q6[$T(@K$
M            ! QWDGVAH7FZQKW3R(6.U\KO5>\\[NAP")"(    FX[L+Z)=
MP/.*OYM40@;OQQV++9>7/:DM$5-         %4C<#\_,V^-V2>[,T7%?#'8H
M[^.>V7D1EH    M$<O\ ] VR7FBVV^9M**G)YEO]4_:N\7E5_P!,?8VZ-'0
M                            8C(?8"\]J++U$\,QQ8MPGL5,1<*$
M 6SL>]@*/VHK?43(IYXKZO".QEQAD               !4PO_9VZ]MK+U8\+
MF."AMQGM8D&    %I_9[Z(]K?-SA'S9K!47\<]LKS'Y=>R&QAJW
M       1B\^^Z/72J#:6L?/@B=3E&4&VL]#DO-NLT58Z25%TLQUN2G$*(R/K
M6%%TI'Q#_E?ZY]YGVG]O]C;\N/3<[K2?U3$Q@Q3V5FV6T3K$\V*8Z8?9W^+G
MHKW>#=>N][7\V37;;;6/TQ,3FR1VVBN.LQI,<N6)Z)1M#XP?8(     F^Y/L
M'F81LC1%8M+CS\KG3<RD1G")*V6;9J)%J^(M",E/TM=&=,C],DW.$_ /3O\
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M(-!?>F*O-3W>28]GL7.#)[S'%O;PET@.3L              "-+O/?HEV_\
M.*CYM7HE;3QSV(6]\N.U".)ZM    =_=VW]H:;YNLE]T\=$?=>5WI>S\[NE/
M.*Y:                               B,[U#]A/[S_X>";L_U=WWH&^_
M3W_<B-$Q7@   )1.Z\_/W='XH4_NRH1-WX8[4[9>*W8FA$%8@
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M."AMQGM8D&    %I_9[Z(]K?-SA'S9K!47\<]LKS'Y=>R&QAJW
M    !Y_*\EK,.QJ]RJY=-FKQ^JFVTU2>'K%,PF%O&RPE1I)R3(4DFVD:ZK<4
ME)=)BI^??.MCZ<^2[KY]\RMR[':8+Y;S[9BE9G2O7:VG+6/;:8B.F5K\C^3[
MWU!\XVOR/Y=7FWN[STQ4ZM;VB-9ZJU\5I]E8F9Z(5Z,URRSSK+<AS"Y6:K'(
M;679OIXU.(CI?</L\)E2B)79H$8D,M%Z#;:2] >0GJ;Y_OO5/J#>>HOF,Z[S
M>9[Y+1KK%>:?RTC7]-*Z4KU5K$/6#TY\BV7IGY%M/D'R^--IM,%<=>C2;<L?
MFO/]5[:WMUVM,O+BC70   #<^P.V3N[&Z..8NXRX[3-OE<9.X@U()G'JQQMV
M<A3B-5-*GK4W$;47WKLA)^#4Q^D?VE]$7]?>N=G\CO6;?+:W]]N9CHTV^.8F
M\:QPG),UQ5GV6R1+\[_NGZSIZ%]%;OYU6T1\QFONMO$].N?)$Q2=)XQ2.;+:
M/;6DPGT:::8:;99;;999;0TTTTA+;333:20VVVV@B0AM""(B(B(B(M"'K%2E
M,5(Q8HBN.L1$1$:1$1T1$1'1$1'1$1P>6U[WRWG)DF;9+3,S,SK,S/3,S,],
MS,],S+]!NU &@N9K:%G>S9S*\-;90Y>M1SO\0<4:4FSE5.R^[6()Q9\#*+-#
MCL%U9Z\#,I9ETD0Z8K^[O%O9[7+-C]YCFOM]G:K-O,O1WG8\AIQA]AQ;+[#R
M%-/,O-*-#C3K:R2MMQM:3)23(C(RT,6JF?F#    #OSN]MX_)_NZK!+64MO'
M-T6X].TE:_P$7+HBG%X[)X3XC2=@3ST$R01&X[(9-1Z-EI'W./FIS1QC[$O:
M9.3)R3PM]J>D5RT              !&EWGOT2[?^<5'S:O1*VGCGL0M[Y<=J
M$<3U:    [^[MO[0TWS=9+[IXZ(^Z\KO2]GYW=*><5RT
M              !$9WJ'["?WG_P\$W9_J[OO0-]^GO\ N1&B8KP   $HG=>?
MG[NC\4*?W94(F[\,=J=LO%;L30B"L0
M $#'>2?:&A>;K&O=/(A8[7RN]5[SSNZ' (D(@   ";CNPOHEW \XJ_FU1"!N
M_''8LMEY<]J2T14T         52-P/S\S;XW9)[LS1<5\,=BCOXY[9>1&6@
M                      "S'RIS9<_ESV>D39#LI\L*K8W7/+-;G40C=A1&
MC4?2:6(L=#:?N)20JLWFV[5U@Z<->QT$.;J         ,1D/L!>>U%EZB>&8
MXL6X3V*F(N%"     +9V/>P%'[45OJ)D4\\5]7A'8RXPR
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MM/'/8A;WRX[4(XGJT   !W]W;?VAIOFZR7W3QT1]UY7>E[/SNZ4\XKEH
M                          "(SO4/V$_O/_AX)NS_ %=WWH&^_3W_ '(C
M1,5X   "43NO/S]W1^*%/[LJ$3=^&.U.V7BMV)H1!6(
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M   #O[NV_M#3?-UDONGCHC[KRN]+V?G=TIYQ7+0
M         $1G>H?L)_>?_#P3=G^KN^] WWZ>_P"Y$:)BO    2B=UY^?NZ/Q
M0I_=E0B;OPQVIVR\5NQ-"(*Q                                0,=Y
M)]H:%YNL:]T\B%CM?*[U7O/.[H< B0B    )N.["^B7<#SBK^;5$(&[\<=BR
MV7ESVI+1%30        !5(W _/S-OC=DGNS-%Q7PQV*._CGMEY$9:
M                 ++7*1]FW9_XHQ_5<L5>;S;=JZP>37L=%CDZ@
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M>.I<.ZK#XE*5_P"GVL=YHC,SXDH)1:D9&*B]9I::S[%WCO&2D7CVMDC5N
M         C2[SWZ)=O\ SBH^;5Z)6T\<]B%O?+CM0CB>K0   '?W=M_:&F^;
MK)?=/'1'W7E=Z7L_.[I3SBN6@                              (C.]0
M_83^\_\ AX)NS_5W?>@;[]/?]R(T3%>    E$[KS\_=T?BA3^[*A$W?ACM3M
MEXK=B:$05B                                @8[R3[0T+S=8U[IY$+
M':^5WJO>>=W0X!$A$    3<=V%]$NX'G%7\VJ(0-WXX[%ELO+GM26B*F@
M     "J1N!^?F;?&[)/=F:+BOACL4=_'/;+R(RT
M   67>4QIUGEOV>0\VXTL\-A.DEQ"D*-I]Z0^PX25$1FV\RXE:#\"DJ(RZ#(
M5>;S;=JZP>37L=$#DZ@        #$9#[ 7GM19>HGAF.+%N$]BIB+A0@
M"V=CWL!1^U%;ZB9%//%?5X1V,N,,@               *F%_[.W7MM9>K'A<
MQP4-N,]K$@P    M/[/?1'M;YN<(^;-8*B_CGME>8_+KV0V,-6X
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M\N.U".)ZM    =_=VW]H:;YNLE]T\=$?=>5WI>S\[NE/.*Y:
M                   B,[U#]A/[S_X>";L_U=WWH&^_3W_<B-$Q7@   )1.
MZ\_/W='XH4_NRH1-WX8[4[9>*W8FA$%8@
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M+_*+UKSY=KZ$V5XY::;G<Z3^J8F,&.>K2LVR6B>/-BM[$E ^T7QZ
M_BDI6E2%I)25$:5)41*2I*BT-*B/4C(R/I(!6FYJ=H%;*[T91B\:.IG'+%TL
MFQ!?5\#2L=N77G6(C.A$DTT\UM^"9_ZQQN+0M2%KAO[S'$^WVJ;/C]WDFOLX
MPYT'1Q    >HPG+[K ,NQS-<=?[-=8Q;PKBO6?%U:W8;R7%1I"4J2;L.8T2F
MGF]='&EJ2?09C%JQ:LUGA+:MII:+1QA:.P'-:7<;"\9SG'G>NI\HJ(EM$U4E
M3C':&_\ $09'#JE,ROE)6P\G_5=;47H"IM6:VFL\87=+1>L6CA+UXU;
M      C2[SWZ)=O_ #BH^;5Z)6T\<]B%O?+CM0CB>K0   '?W=M_:&F^;K)?
M=/'1'W7E=Z7L_.[I3SBN6@                              (C.]0_83
M^\_^'@F[/]7=]Z!OOT]_W(C1,5X   "43NO/S]W1^*%/[LJ$3=^&.U.V7BMV
M)H1!6(                               "!CO)/M#0O-UC7NGD0L=KY7
M>J]YYW=#@$2$0   !-QW87T2[@><5?S:HA W?CCL66R\N>U):(J:
M *I&X'Y^9M\;LD]V9HN*^&.Q1W\<]LO(C+0   !:(Y?_ *!MDO-%MM\S:45.
M3S+?ZI^U=XO*K_IC[&W1HZ                             #$9#[ 7GM
M19>HGAF.+%N$]BIB+A0@    "V=CWL!1^U%;ZB9%//%?5X1V,N,,@
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M-IU6HY,E9^E0(6ZQ],9([UCL\G1..>V/O2Q"&G           C2[SWZ)=O\
MSBH^;5Z)6T\<]B%O?+CM0CB>K0   '?W=M_:&F^;K)?=/'1'W7E=Z7L_.[I3
MSBN6@                              (C.]0_83^\_\ AX)NS_5W?>@;
M[]/?]R(T3%>    E$[KS\_=T?BA3^[*A$W?ACM3MEXK=B:$05B
M                      @8[R3[0T+S=8U[IY$+':^5WJO>>=W0X!$A$
M 3<=V%]$NX'G%7\VJ(0-WXX[%ELO+GM26B*F@        "J1N!^?F;?&[)/=
MF:+BOACL4=_'/;+R(RT    6B.7_ .@;9+S1;;?,VE%3D\RW^J?M7>+RJ_Z8
M^QMT:.@                             Q&0^P%Y[467J)X9CBQ;A/8J8
MBX4(     MG8][ 4?M16^HF13SQ7U>$=C+C#(               "IA?^SMU
M[;67JQX7,<%#;C/:Q(,    +3^SWT1[6^;G"/FS6"HOXY[97F/RZ]D-C#5N
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MODO_ "A]:_"?+=MZ&V5_][=3&?<:3TQBI;_:I/T7R1-Y]L>ZK[+)31]V/B0
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M\N.U".)ZM    =_=VW]H:;YNLE]T\=$?=>5WI>S\[NE/.*Y:
M                   B,[U#]A/[S_X>";L_U=WWH&^_3W_<B-$Q7@   )1.
MZ\_/W='XH4_NRH1-WX8[4[9>*W8FA$%8@
M    (&.\D^T-"\W6->Z>1"QVOE=ZKWGG=T. 1(1    $W'=A?1+N!YQ5_-JB
M$#=^..Q9;+RY[4EHBIH         JD;@?GYFWQNR3W9FBXKX8[%'?QSVR\B,
MM    %HCE_\ H&V2\T6VWS-I14Y/,M_JG[5WB\JO^F/L;=&CH
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MCK'&U[VBM:Q],S,0B[[>[;Y;LLWS#>WC'L\&*V2]IX5I2LVM:?HB(F5A#:W
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M#<;/[AI,566-,ENV5WAG7%7_ $PW2.;H
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M50\K3[B3/T!'W4:XN]*VDZ9NZ4_ KEJ
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M1&&0                           &(R'V O/:BR]1/#,<6+<)[%3$7"A
M    %L['O8"C]J*WU$R*>>*^KPCL9<89                5,+_ -G;KVVL
MO5CPN8X*&W&>UB08    6G]GOHCVM\W.$?-FL%1?QSVRO,?EU[(;&&K<
M     0P\Z&Z/O[W2=QFNDD]C^WJ7Z1CJU:LOW[RFE9%)U(^E3$AEN'T]!'%4
M9="C,_-K_)/UU_RGUU;Y)L[\WRCY1%L-=.%L\Z3N+=M;17#VXIF.BW3Z(?X[
M>B?^,>B8^<[NG+\U^;37-.O&N"-8P5_\59ME[,D1/A<?#YW?OX   #]6&'I3
M[,:,TX_(D.ML1V&4*<=>>>63;333:"-3CCBU$22(C,S/0;XL67/EK@PUF^:]
MHK6L1K,VF=(B(CIF9GHB/;+GERX\&*V;-:*X:5FUK3.D1$1K,S,]$1$=,S[%
M@#8[;5G:?;+&L.T:591XQS\@D-<!E*R"R,I-FOK$$1/M17%%&96?2<=AO4>M
M7]K_ $7C] ^B=EZ=_+.]I3WFXM&GYL^3\V2=8\45G3'2>,XZ4>5_]RO6&3UU
MZRWGJ#\T;.]^3!6=?RX,?Y<<:3PFT:Y+QPB][-M#] ?P@              (
MIN\MV=[=3XUO73Q4]HI5,XEF*FFSXW*N;(6YCEF^:=$$F#9O.1%K/5:SF,)U
MX4$13-K?29QSVP@[S'K$9(XQT2AS$U7     "=WN[]X_?UM3(V[MI*5Y#M@Z
MU"ADM9==,P^Q4\[3.D1Z&LZF0AZ&KA+A;91'XCXE]-?N:<M^:.$_:M-IDYL?
M)/&OV)"!&2P       '#'>(XZY><MUE8-H)?O2R[%LB<\)J0V\_)QA2TD1&9
MFD\D+7P:)U/T!(VTZ9=.N$;=QKAUZIC\$ (L52    ]+AN77F!95C^9XU+[%
M>XU:1+>LD&DUME(B.$OJ9#1*23\.2C5IYHSX76EJ0?09C%JQ:)K/"6U;32T6
MCC"PUL9S<[3;TT\ DWU;BF:&PRBUPV_GQX$Q,[@03YT<B4MEB^@*=,^K4R9O
M$C0W6FS/05N3#?'/#6O6ML6XQY(XZ6ZG4J5)6E*T*)25$2DJ29*2I*BU)23+
M4C(R/H,<7=_0                            $1G>H?L)_>?_  \$W9_J
M[OO0-]^GO^Y$:)BO    2B=UY^?NZ/Q0I_=E0B;OPQVIVR\5NQ-"(*Q
M    %8[?C?S-M]<RMKR^MIZ,=[?)][&*IDNHJ**I2ZI,!I$)"RC.V2HQ).3)
M-)N/.ZGJ2"0A-KCQUQUTCC[94N7+;+;69Z/9#18Z.0
M       ^F%"EV,R)7P([LN=/DL0H<5A!N/R9<IU#$>.RVGI6Z\\LDI(NDS,.
M'3/!GCT1Q6F-I,':VUVQP3 VR;->+XQ4U<UQG_92+1J*A=O,1_9-M7'G?_UB
MHO;GO-NN5WCKR4BO5#8@U;@        "#'O)]O7<>WBI<^88,J[<+'(Z),CA
MZ%9!BJ&*B6VI1%H6E&NN-.O2>BM.A(L-K;6G+[8E6;RFF2+^R8^Q'0)*&
M  /IBS9D):G(4N3$<6G@4N*^['6I&I*X%*:6A1IXB(]#Z-2!G68X/M\?WO\
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M&B8KP   $HG=>?G[NC\4*?W94(F[\,=J=LO%;L30B"L0        !4:%RH
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M#4>KKKDCA+1LQ8[;)S4Y9XQ]BKW>/EOSQX;?:C]$A$
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M5'%=N?-[EMM/)CMEW0(Z2        Q&0^P%Y[467J)X9CBQ;A/8J8BX4(
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MX]:SZ:UB+Z3CSZV4[#E-<1="TI>:/11="BT,N@Q;Q,3&L<)4DQ-9FL\888&
M   '5W)GO'Y'=[J"782"9Q;,3;PW*.L<)$>-$M94?Q=<.&M1--%36S;+KCAD
M:DQ#?2G[\QQSTY\<Z<8Z4C;Y/=Y(U\,]$K&XK%N        UGN_M7C6\^ 7N
MW^4-F4*V9)<*P:;0Y,I+>-JY6W, UFG23!?\*>))/-*6TL^!Q1'O2\X[<T-,
ME(R4FEN"M5NIM?ENSV:V^"YG 5#M:QPUQY*"6<"YJW''40;NH?6E':JRP0T9
MH5H2T*2IMQ*'4+0FTI>MZ\U>"FR4MCMRVXM=C9H
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M7'*BMD76]8A*GBGX=Q%ORWZ+*W/M9K^;'TUZNI&R)2$
M     "?WN[?LVUGQOROU5'%=N?-[EMM/)CMEW0(Z2        Q&0^P%Y[467
MJ)X9CBQ;A/8J8BX4(     MG8][ 4?M16^HF13SQ7U>$=C+C#(
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ME*B-QAPFY#/$7&A.I&=E3)7)&M53DQ7Q3I9I\;N8
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MW 7629;Q((W'G5+=<,M5*,^D1)M-IUM.LIU:UK&E8TAZ489
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MAXD9N%%C0V>+J8D=F,UQF2E]6PVEI'&HB(C5PH+4]"Z14+OAT/H
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M-?1F#TG;+6GSWY?.2/=S,1;)BMDMEKDI'ZHKS\E].FLUUM$1:LSQ0/F=]&@
M $1F9$1&9F>A$729F?@(B^Z$1,SI'%B9TZ9X.T>6SE8R;/,@J\KSFFETF 5D
MEJ<J/:QW(DW*W&%$ZQ API"$O^*'7"3VB0I*4.-:MM&I1FIOZ4_LO_8GYWZJ
M^;X/GWJC;9-KZ3P7B_+EK-+[J:]-:4I:.;W4SI[S),16U=:8YFTS:GSM_>#^
M]WR;TQ\JS_(_36XQ[GU3FI-.;%:+TVT6Z+7O>LZ>]B-?=XXF9K;2UXBL1%YC
M2(B(B(B(B+0B+H(B+P$1>@1#T9B(B-(X//J9F9UGB_H
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M= B04$A2S=4@DQFFBX5.'Q&7@-73X1B9F>+,1$<&4&&0
M       'S2X<2>PJ-.BQID=?W\>6PU(87X2],T\E;:O#Z) :1/%XN5M5M?.<
M)V;MO@4QU*";2[*P_'I#B6R4I1();M<M1()2S/3734S^Z-N>_7/\6O)2>,1_
M!\WD>VC^JW;GY$8S^3 Y[]<_Q8]WC_;'\#R/;1_5;MS\B,9_)@<]^N?XGN\?
M[8_@>1[:/ZK=N?D1C/Y,#GOUS_$]WC_;'\#R/;1_5;MS\B,9_)@<]^N?XGN\
M?[8_@>1[:/ZK=N?D1C/Y,#GOUS_$]WC_ &Q_ \CVT?U6[<_(C&?R8'/?KG^)
M[O'^V/X'D>VC^JW;GY$8S^3 Y[]<_P 3W>/]L?P/(]M']5NW/R(QG\F!SWZY
M_B>[Q_MC^!Y'MH_JMVY^1&,_DP.>_7/\3W>/]L?P/(]M']5NW/R(QG\F!SWZ
MY_B>[Q_MC^!Y'MH_JMVY^1&,_DP.>_7/\3W>/]L?P/(]M']5NW/R(QG\F!SW
MZY_B>[Q_MC^!Y'MH_JMVY^1&,_DP.>_7/\3W>/\ ;'\&9I, P3&91S\<PK$L
M?G&@VSF4F-T]5*-M1*2I!R($-AXT&E1D9:Z:&83:T]$S,LQ6L=,1$2]:-6P
M         ,?95-5<Q^R7%97VL4EI<*-90HTZ/UB?O5]3*;=;XT^@>FI#,3,<
M&)B)XL!Y/L"^!&(?)JF]9#/-;KECEKU0>3[ O@1B'R:IO60<UNN3EKU0>3[
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MM9>@9&1C'-;KEGEKU0].,,@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                             AOYO^:O?O:W??)\,P3//$6-5U=C3\.M
M]Z^&6?4NV%!7S9:^V7&.V$]SKI3ZE:*=42==$Z$1$)V##COCBUHZ>]7[C/EI
MEFM9TCH]D.8_Y[>:OZT_T'VX_5 =?A\/5]<_BX?%9_W?5'X'\]O-7]:?Z#[<
M?J@'P^'J^N?Q/BL_[OJC\#^>WFK^M/\ 0?;C]4 ^'P]7US^)\5G_ '?5'X'\
M]O-7]:?Z#[<?J@'P^'J^N?Q/BL_[OJC\$V7+#FF3;B;$;>9GF-EXXR6]KK)^
MULNQU]?VIV/?VT)E?8ZN+"@,<$6,A.C;2"/AU/4S,S@9:Q7)-:\%EAM:^*+6
MXRWT.;J    BDYZ>93>O9S=O'<8VWS3WN4<[;JHOI4'WN8G;];:RLFRZO?E=
MIOJ&TF(XX=6PC@2X39<&I))2E&<S;XL=Z3-HUG7Z?H0=UFR8\D5I.D:?1UR]
MGR$;_;M[TV^Y<7<S+/?*QC];C,BH1XAQFF[([82KIN8OBH*:J6_UR(C9:.FL
MD\/I=-3UUW&.F.(Y(TU;;7+DR3;GG73L24"*F #0O,]FF3;=[$;AYGAUEXGR
M6BKJU^JLNQU]AV5V1?U,)Y?8[2+-@/\ '%DK3HXTLBXM2T,B,NF*L6R16W!R
MS6M3%-J\81 [;\Z_,W?[B8%16VYG:ZJZS3%JFSB^\S;]CM-?8WD&'-C]?&Q1
MF2SUT9Y2>-M:%IUU29'H8FVP8HK,Q'3IURKZ;G--XB;=$S'LC\$_ KEJ
M (Z>?S??=;9/R3^3'*O>S[YO?WX[_P#0\<N>V^)O>;XM_."GM>S=F\:R/]CU
M?'UGI^+A3I*VV.F3FYXUTT^]$W67)CY>2=-=?N1T_P ]O-7]:?Z#[<?J@)/P
M^'J^N?Q0_BL_[OJC\#^>WFK^M/\ 0?;C]4 ^'P]7US^)\5G_ '?5'X'\]O-7
M]:?Z#[<?J@'P^'J^N?Q/BL_[OJC\&U]B^<GF1S+>3;+%,DW&\8T&0YK05-Q
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M'N!JV
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MRQQ]K>HYNH
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M+9BWIX([(4>3S+=LIY^1+[*FUG_OC_Y'R\5VX\Z>[[(6FU\BO?\ ;+KD<4@
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MG$DMMQMQ!FA;:T&1D9&9&1ZD.3L_0
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MM<66N6G-'%O,<W4
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MXUC73XCB7HLV#,91(BRH[J#-+C,AAQ*DJ+H,C%5,3$Z3Q7,3$QK'!]PPR
M  (N.\RW2.JQ+$=HZZ2:)>53/?3D;3:M%>(:1Y3%/%D)XM%1[&\XGD^E/\)7
M%TEX#E[6FMIO/L0M[?2L8X]O2AZQR[?QK(*/(HT2!/DT-M77,:%:L+E5DJ16
M2VIK#%A%0ZPJ3#<=9(G&^-)+1JDST,3IC6)CK5T3RS$]3N7^I)S#?^"VZ^35
MG^L0C_"XOI2OC,WT?P?A*[QK?V=&DPIE9MK)B2V'HLJ.]C%DXS(CR&U-/LNH
M5D)I6VZTLTJ(^@R,/A<?TGQF6>K^#@E1DI2C))((S,R0GB-*2,]22DUJ4K1/
M@+4S/^T2$1/OW?.Z?O\ =CV<5G22>O=KYQ8V^E2C4^O'9A.SL7DKZ>%+3;"7
MX+1%IZ2!T]/2==N:<N37V2M=I?GQ<L\:]'X.[1'2@    !4PO_9VZ]MK+U8\
M+F."AMQGM3I;"\IO+SENR^U^39%MG66=[>X306EM8.VN1M.3)\N R[)D+;C7
M+,="G7%&9DA"4EZ!$*_)FRUR3$3T:K3%@Q6QUM->F8;:_DLY8/JEJ?QSE7Y>
M&GO\O[F_PV']L?6V=A.QVT&W$A$S"=N<3Q^P;3P-VL6ICNW*$<)H-"+B6F1:
M)2M)GQ$3VBO1U&ELE[>*9F'2N+'3PQ$2VJ-&X      *I&X'Y^9M\;LD]V9H
MN*^&.Q1W\<]LK%G*1]FW9_XHQ_5<L5F;S;=JWP>37L=%CDZ@       .:><2
MD>R#EGW=@,,D^MC'&+M2#,RX6<:N:O(Y+WI3(]8\>J4Y]P^'IZ!UP3IEKVN.
MXC7#:/H^Q7(QVW<Q_(**^:2:W:2XK+=I"5*0I3E;-8F(2E:32I!J4R1$9&1D
M+28UC13Q.DQ/5*UU2W%;D-/57]/*;G5-W70K:LFLF2FI=?8QFY<.0V9>%#T=
MY*B_L,4\Q,3I/%>Q,3&L<)9,89?'8V$*HKY]M9R6H5;60Y5A83'U<+$2%"87
M)ER7E=/"TPPTI:C] B"(UG2.),Q$:SP52\SO4Y1F&5Y,ALV49%DM[>H9,N$V
MDV]I*L$MFGC<X304C33B5IIX3\(N*QI6(ZH45IYK3/7*PUR45,JFY7MIH<Q"
MFW7JR]MD)6GA,XM]EV07D%9%Q*U2Y"L6U)/T2,CT+705N>=<UO\ KV+;;1I@
MKK_UTNIAQ=P      0,=Y)]H:%YNL:]T\B%CM?*[U7O/.[H=%]UK[!;R>VV%
M^H\D'+=\:][ML>%NV$K@AIP      (H^]*]@MF_;;-/4>-B9M.-NY!WW"O;+
MEWN[?M)5?Q1ROU(P.NY\KO<-GYW=*?X5RU     %8SF3V\D[7[W[B8FZP;$)
MO(9MO1GP$AIW'[]P[BF-DT_@W"CPIB6%FGH)YI:="-)I*VQ6Y\<6^A2YJ<F6
M:^S5)YW<.]E=>8/,V5MYB6LBQ"1/M\89?6E)VF+6<I4V;'B&H^)V52W$IY;B
M3/7L\EO@(TMN&F)NL<Q;WD<)3=GDB:^[GC'#L2;B(F@#SN69;C>"X]9Y7EUO
M$HL>IF$R+*TFFLF(S:W6V&BX6D./.NO/NH;;;;2IQQ:B2DC,R(9K6;3I7IEB
MUHK'-;HB'T8]DF/Y;4Q+[%[NKR&EG(XXEI33HUC!?+HXB;DQ7'6C6@ST4G7B
M2?09$?0$Q-9TGHDB8M&M9UAFAAD     >?QW*\:RZ/.EXQ>U=]&K+:PHK%ZJ
MF,3&X5Q5/G'L*Z2;*U=3*C.$6J5:&:5)46J5),\S6:\6(M6W36=7H!AEX[,M
MO<&W#KEU.<8G0Y3 4A2$M7-;&F.1^(C+K(4EQLY4!]/$?"XPMMQ)GJ2B,;5M
M:LZUF8:VI6\:6B)A /SF[!4.PFYT.MQ&0\K$\KIO?!3ULN0N5-HEIFR84VI5
M)>6N1,A,N,I7'>=,W30YP+-:VU.+L<&2<E-;>*%5N,48KZ5\,NA>Z^N)S.X.
MYN/H=,JRPPVNN)#&OI53J>[9A0W2+T#1'O'R/[O$7W"'+=Q^6)]NKMLIGGM'
MLT32""L0
M                       %:7FW^TEO!\;Y/J6(+7#Y5>Q3;CSK=J7+N[?L
MVUGQOROU5'$+<^;W+#:>3';+N@1TD      $&'>;?3SB7FBH?GEGPL-IY<_Z
MONA6;WS8_P!/WRV+W6WL_O'[489ZMR(:[OA7O;['C;LA,4(*P '+G.G]F#=K
MVIIOG50CM@\VKAN?)MV?>@"V?^EK:[SBX3\Y:P6-_!/9*JQ^97MA:@%0O
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MO!)L(B:
M                       K;\V+5.KF.W=-^=9-O'ELGK$-5,5YM*NRQ>A#
MJ[F.I9?VFA/^@6F'7W5>Q3[C3WUNU+/W>J8R>7&M*(\^^S[[<JT7(CMQ7.+M
M3'$75-2IB2(O0/CZ?N$(>Y\WN3]IY,=LNX1'20      0?=Y:W6KWUQ,YDN<
MP[Y):(DHC5T>6V;?OQSS11N.V<)25FHS+AX#(B(CUZ="G[77W<_ZONA6[S3W
ML:_M^^6P^[ 17HOMX.Q29D@SJ,-ZPI4%B&22[9D/":#:L9QK,SUUU).G]HUW
M>NE>]MLM-;:=4)?A"6  YAYS"85RR[KE)<=:9.II^-QAE$AU)>^BBTX&7'XR
M%F:M"Z5IT+I_L'7!YL..X\FW8@2VB9I"W8VP-NPM%++</"C0E=/$0A2_?)6<
M*5+3>.&A)GX3)*C(O0/P"QOKR3V2JL>G/7CQA:+%2NP    !$QWHR("_(;VV
M3+CZ>4SJNRPF9G'KY/N/K.NL(/5\.A::<6NI^#3IF;37\W=]Z!O=/RZ_3]R)
M?J:+_,K;\2P_R^)O2@='T_\ 7>=31?YE;?B6'^7PZ3H^G_KO.IHO\RMOQ+#_
M "^'2='T_P#7>WARTM4Q<P.S9LS[-QTMQ,7-M#M1%:;4OQI'X4K=3=O*;29^
M$R0HR^X8YY=?=V['7#I[VO:LOBJ7(     K;\V+5.KF.W=-^=9-O'ELGK$-5
M,5YM*NRQ>A#J[F.I9?VFA/\ H%IAU]U7L4^XT]];M2H=W&F*GE^FE#>D/M>4
M3(S-<F,W$<X_%>.ZI)IJ7,2:2+30^/4_N?=A[KS.Y.V?E='6[X$=*1T]Y"C;
M-S:O&BRV3+BYL60.JP!RK@QI\]2"99/)FIC,FPK4HQ]R+V<GUI<4XB7V4R0H
MN(A*VO/SSR^'VHF\Y/=QS>+7H1!;7LV_E$PKR<V60^_GWR57O7['2Q.L\;=K
M;[-UNE_P=BUU[1UGX+L_'UGX/B$V^G+/-IRZ*^FO/')KS:]'_6JT-6G8G70#
MN$PD6QPHIVB*U;[M<BQ-AOMJ8#LIMF2Y"3)XB:4XA+AMZ&HB/4A43IKT<%U&
MNG3Q?:#(  -0[_%DI[*;I%B"E)OSPF_*(MI+CDM#!P'2LUUK;*VW'+A%5UYP
MDDI/%+)LC4DC,RWQZ>\C7AJYY=?=VY>.BL=U-%_F5M^)8?Y?%MTJ7H^G_KO6
M5^6!.()Y?]J$X*ZX]C:<2A)9>?8;C2G;4G'RR5V;&9D2V8]@YDO;#D(0ZZA#
MYK)*U)(C.JR\WO+<W'5<X.7W5>7AHWP.;J .+^?E.&KY<<A3E[TF.Z=YCQXF
M["C-3)A944M9QTL1WY<%E2'*4IR7S4X1HC&XI)*624GWVW-[V.7O1MUR^YGF
MZ^CM0(5+,3QK6>);+(?''C"'XI[#2QNV^,^TM]@['U5_UG:NU<'5\/IN/33I
M%C.NG3IHJXTUZ-=?^OI6J:'QP=%2GD)14W_BFN\>)@J-4(KCL;/C,H:C2@U1
M2F\?5F9%JC3H(5$Z:]'!>1KI&O%EAAD   !5&OF:+Q[=:V-L1^-K'4BI89EK
MVQ[70_'Q:D+B-=%'.FL\>*R1RT$T7+[LX3*W'&BV\Q@FUNMI9<4CQ8QHI;2'
M7TMJ,O"1+41?=,5>7S+=JWP^57L;Q'-U         %5W/F:,\ZS3BL;4E>^W
M(^(DTT1225XXF:DE1WJ#41'X#T+7[@MZZ\L=BDOISSVR\EU-%_F5M^)8?Y?&
MW2TZ/I_Z[SJ:+_,K;\2P_P OATG1]/\ UWG4T7^96WXEA_E\.DZ/I_Z[TU?=
MF(AHVGSXH3\F0@]PUFM4J(U$6E?O;H_2I0U-FDI.FG2:B/7T/1$#=^..Q9;+
M3DG3K22"*F     #EWFR_E_\FKGE_P"I\5=<][V^P?GGXXZM'%[SNJ_Q7;.'
M@Z[B_P %P</:OP8[8?><_P#M\?J[W#/[KD_W>'U]ROMF\;;1F<M>V]UG5E6.
M.*4B+F^,4%+.AL]/ TN=0Y=?Q[-PO164>(1Z_>%ITV5>?]6FOT?_ $55N37\
MDSI],?S>%&6CVF&1MNWYQ*W#NLTJJQMQ"E-89C%'?SI;):=8T4B\R[&X]<XH
MM2)?52B+PF@_ ,6YM/RZ:_3_ /1O7DU_/,Z?1'\X3_\ *%_+MY/5^0#3J-87
MOM\<:>_OQGU3O9_??Q^FZS_:]1V?_P!.UZSLWI>,5N;WO-_N?R[EKM_<\G^U
MW]?>ZR'%W        03]XVW6*Y@H9RYD]AWR>8X7!&KH\IO@\9Y#HKK7;6&K
MB,]=2X-"^Z8L-KK[OO5F\T][T]3H?NOT0446\/8I$N01VV&=8<J$S#-)]CR+
MAX":GSNL(^G77ATT]'7HY;O76O>Z[+32VG7"5$1$X      $5W>@(@KHMGNV
MR)<<BMLSZLXL)F8:C['CO%QD[/@]61=&FG%KKZ&G3+VFNMNY!WNFE=>N7,7=
M[-U:>8ZL.),L'GO>EE6C<BMCQ6S3V5CB,W6[:6HC(O 7!T_=(=MSK[KO<=II
M[[HZI3W"N6@      (S>=U/* J3P[D.VK&ZJFV")[:R/62\T:C&UI'<RF-/D
MP\>D0T(ZLR1/>:GJ8T*.I*-3$O;^^_1X/IX(>Y^'_7X_HXH:\BCXO'GJ1B5M
M?W%7JHT2<BQZNQN>1:EP)5!K,GRJ.9Z:ZF4@O!X.GHFQK[=-?^NQ73RZ_EUF
M/X??+ #+5TUL1'Y6F\AIWM[+C<>6TY*;)VNBXW6U^&13+0R7?7-7E5GEL^O4
MK4E(AP(SA=!FHT\1#ED]]I_MZ?>[XO<:_P"YK]WVZK%&(^]7WL4?O'\2^]'Q
M='][WO<[)XC\6<'^'\6]A_PG9N'P<'1KKKTZBLMKK/-XEO7ETCETY7HQAD
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M+L'9?\-V+LW#U75_@^KTX>C05DZZ]/%;1IIT<'V@R
3                      /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>dnli-20210503_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dnli-20210503.xsd" xlink:type="simple"/>
    <context id="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001714899</identifier>
        </entity>
        <period>
            <startDate>2021-05-03</startDate>
            <endDate>2021-05-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl80L2ZyYWc6MzUwM2E0MjY0ZTNjNDRmYTg5MGUyYmM2MDEwMzliNjUvdGFibGU6MzMwYTM0NzJiY2NiNDllZGJmNWQ2YjRmOWUwOTEzOGIvdGFibGVyYW5nZTozMzBhMzQ3MmJjY2I0OWVkYmY1ZDZiNGY5ZTA5MTM4Yl8yLTEtMS0xLTA_525d213b-4b67-412b-b512-a4e44a9f8408">0001714899</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl80L2ZyYWc6MzUwM2E0MjY0ZTNjNDRmYTg5MGUyYmM2MDEwMzliNjUvdGFibGU6MzMwYTM0NzJiY2NiNDllZGJmNWQ2YjRmOWUwOTEzOGIvdGFibGVyYW5nZTozMzBhMzQ3MmJjY2I0OWVkYmY1ZDZiNGY5ZTA5MTM4Yl8zLTEtMS0xLTA_23b2d1e3-de1e-4195-8db5-cf87d2104dee">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV85NDQ_0a1f1af9-8e72-48d4-ab82-f610c92610f5">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8yMzI_94f65d02-1fc2-4d13-b717-72960a380757">2021-05-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8yMzc_eba6ec90-48e1-4ac3-94b8-ed9dcfd5e3b8">Denali Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6MGJjMWY0ZDFlYzBkNDI2MmI3OWRlMWQwZDA3NmQ2Y2EvdGFibGVyYW5nZTowYmMxZjRkMWVjMGQ0MjYyYjc5ZGUxZDBkMDc2ZDZjYV8wLTAtMS0xLTA_4ca3dfb4-8f3e-4d8a-84d1-10e35c0cca33">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6MGJjMWY0ZDFlYzBkNDI2MmI3OWRlMWQwZDA3NmQ2Y2EvdGFibGVyYW5nZTowYmMxZjRkMWVjMGQ0MjYyYjc5ZGUxZDBkMDc2ZDZjYV8wLTItMS0xLTA_dea94927-7414-4218-aa69-d0d098bcfab8">001-38311</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6MGJjMWY0ZDFlYzBkNDI2MmI3OWRlMWQwZDA3NmQ2Y2EvdGFibGVyYW5nZTowYmMxZjRkMWVjMGQ0MjYyYjc5ZGUxZDBkMDc2ZDZjYV8wLTQtMS0xLTA_56c4dabf-3853-4e3d-98e8-2335ae832d0e">46-3872213</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8zMDA_bdb26f0b-d797-46c1-8e96-cd4616f191c0">161 Oyster Point Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8zMDM_929902c5-e3f8-4cd2-8195-ed8fce1e9f4f">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8zMDc_2e3d6f15-faab-41c9-9e2f-bd9eb5a6d589">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8zMTA_e17877be-bd6f-418e-9cce-2003e839bc63">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8zNzg_bd8e12ef-89f3-45be-acfd-787d7ec8131e">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGV4dHJlZ2lvbjo4YmIzODFjZmI3ZTg0ODA1OTFhZGZhMzJhNjhhNTE2ZV8zODI_9cf5dea2-9097-4b5d-b28f-44ef8a8695cb">866-8548</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6YTBlYmUxMTRhYTM4NGFmZGJjNmRhYWU0MjEzNDU4ZTQvdGFibGVyYW5nZTphMGViZTExNGFhMzg0YWZkYmM2ZGFhZTQyMTM0NThlNF8wLTAtMS0xLTA_7be14301-67b2-418f-bf74-b236a07e550b">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6YTBlYmUxMTRhYTM4NGFmZGJjNmRhYWU0MjEzNDU4ZTQvdGFibGVyYW5nZTphMGViZTExNGFhMzg0YWZkYmM2ZGFhZTQyMTM0NThlNF8xLTAtMS0xLTA_5c4f7ec2-0a48-443d-8b39-55e9ebc600bc">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6YTBlYmUxMTRhYTM4NGFmZGJjNmRhYWU0MjEzNDU4ZTQvdGFibGVyYW5nZTphMGViZTExNGFhMzg0YWZkYmM2ZGFhZTQyMTM0NThlNF8yLTAtMS0xLTA_20d17709-d67c-42f7-b885-f48e01f7350e">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6YTBlYmUxMTRhYTM4NGFmZGJjNmRhYWU0MjEzNDU4ZTQvdGFibGVyYW5nZTphMGViZTExNGFhMzg0YWZkYmM2ZGFhZTQyMTM0NThlNF8zLTAtMS0xLTA_03b408e1-97a8-44c7-948d-11b29a35aa31">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6NTc5NWFjMTIwY2EzNDhmZGJlNzYxNmIyMDIyMDYwZTkvdGFibGVyYW5nZTo1Nzk1YWMxMjBjYTM0OGZkYmU3NjE2YjIwMjIwNjBlOV8wLTEtMS0xLTA_cf800afe-44f7-4bba-9426-2047327dfad9">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6ODg1ZDMzYWY5ZGE5NGIyNWJjMzk4YmMzZTQ1ZTFkYWYvdGFibGVyYW5nZTo4ODVkMzNhZjlkYTk0YjI1YmMzOThiYzNlNDVlMWRhZl8xLTAtMS0xLTA_497e423c-05ab-43fb-91c8-63dc61e73df1">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6ODg1ZDMzYWY5ZGE5NGIyNWJjMzk4YmMzZTQ1ZTFkYWYvdGFibGVyYW5nZTo4ODVkMzNhZjlkYTk0YjI1YmMzOThiYzNlNDVlMWRhZl8xLTEtMS0xLTA_a10543a0-6aa6-4b70-8fd9-5b0e3d669406">DNLI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503"
      id="id3VybDovL2RvY3MudjEvZG9jOmRmOTVkN2RhNzFiMzQzM2NhZDNhMDcwMmFjMDUwYzM2L3NlYzpkZjk1ZDdkYTcxYjM0MzNjYWQzYTA3MDJhYzA1MGMzNl8xL2ZyYWc6OGJiMzgxY2ZiN2U4NDgwNTkxYWRmYTMyYTY4YTUxNmUvdGFibGU6ODg1ZDMzYWY5ZGE5NGIyNWJjMzk4YmMzZTQ1ZTFkYWYvdGFibGVyYW5nZTo4ODVkMzNhZjlkYTk0YjI1YmMzOThiYzNlNDVlMWRhZl8xLTItMS0xLTA_770d84bd-97da-4179-bfb4-28b215f00238">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140154847292200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  03,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Denali Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3872213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">161 Oyster Point Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">866-8548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DNLI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001714899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*0:S;%4S.Y68R#/;
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ 4$2C4F60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( %!$HU+S WT2[P   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( %!$HU*97)PC$ 8
M )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ 4$2C4N@B[A@X!   /A   !@              ("!#@@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( %!$HU*?H!OPL0(
M .(,   -              "  7P,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  - 3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="dnli-20210503.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.denalitherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="dnli-20210503.htm">dnli-20210503.htm</File>
    <File>dnli-20210503.xsd</File>
    <File>dnli-20210503_cal.xml</File>
    <File>dnli-20210503_def.xml</File>
    <File>dnli-20210503_lab.xml</File>
    <File>dnli-20210503_pre.xml</File>
    <File>ex991pressreleaseq12021.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dnli-20210503.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "dnli-20210503_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dnli-20210503_def.xml"
     ]
    },
    "inline": {
     "local": [
      "dnli-20210503.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dnli-20210503_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dnli-20210503_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "dnli-20210503.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "dnli",
   "nsuri": "http://www.denalitherapeutics.com/20210503",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210503.htm",
      "contextRef": "i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.denalitherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dnli-20210503.htm",
      "contextRef": "i78da5c8cba5948dbb1e56dba071e3a93_D20210503-20210503",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.denalitherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001714899-21-000050-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001714899-21-000050-xbrl.zip
M4$L#!!0    ( %!$HU( VG, FA4  /V<   1    9&YL:2TR,#(Q,#4P,RYH
M=&WM/6ESVLBVW^=7]&/>F^M4I4'[@A/?<@SVD%@BP3@>^))JJ5N6L) 829CE
MU[_3$MC@%3MX(7&JD@"]GS[[.=W]X;_C?HC.69(&<?2Q)):%$OKOSH?_P?B?
M3ZU#5(O=89]%&=I+&,D81:,@\]$)9>D9\I*XCT[BY"PX)QCG;?;BP20)3OT,
M28(D7BE,JIHNB)HA2UCW# ,K.O6PJ0L$ZXPXCDPI)4Q[?UJ57-DQ'4G&KJZ8
M6#%5#SN2(F-/U*BN:8HI&>I[6J6>J5*=$EUT9$6674)E(NB"1%Q!%5Q9X\/Z
M&:P.5ABE'TM^E@VJE<IH-"J/Y'*<G%9$TS0K8UZG5%2JCITD#):J\E_RRI(@
MR)4@2C,2N6Q>/QAG.&7N4@OX7CZ-SZ%N&$2,@[&2)21*O3CIDPS #%V)*A8,
M+(OS?J#FV1W#\F*'I(O#WES[OC$E+&F7G=PVHB@O=#2O3MDE8/*Z\W5" ;21
M!"R("RL:I\%-((?EB)5_K,,CUV=]@J_"<WP-$$M;Q4OSJM601*<?2RS"QT<E
MV&9&Z,Z'/LL(XDTQ^W<8G'\L[<51!LB+VY,!C. 6WSZ6,C;.*OFN5W;^^../
M#UF0A6R'PHHQ1UO 'OE#I?CQ0Z7HVHGI9.<##<Y1FDU"]K%$@W00DDDUBB,&
M$PC&55Z1)<7'@%(6Y1^AW 8*2@*W&'^<M9CWL13H!B6J:[@.44W%H(XC,E6C
M#B"PR&1BRC]J\ZE<S*F$(M+G0[.@6H]@?I,]6$Y"PD9$V?@+FY100*%K*G^?
M.+7X_%!JG7=D:TA[]?/N@=EK]EO]9OO[F2VU?'NZ'UC3;U-+LOUNS?:MFCNR
M^OL]JW8\ZL"OA[(==J:#LV[O3.S6Z%FG[8X[/4NPIG:O<_)MVFGORE;ML]^9
M[HK6 ?P:&L*AU)UT3ES-FAZ/+*DN6+V.T&W;/;O6ZG?:IZIU<#SI]"W)JM5'
MUC0,[-[Q.3W8#YR#8VACC3IM2["GGX..9 =V+0R[!Y_[]LDWJ=.#>9\<CYKM
M^K1YT)BU^0YCJ5&W'4^MZ2<?UB);_<^]CM00FB??SSK]#LR[&]@'';7;WE6M
MMJ5T0F-RV*YGUI$P/FSO_E EE4JB[&#%T72LB)*#'564,%&8HA#3,Q3!*.T(
M@+"ZJ!BF^:&RM)_KW]Z"6*'U.*LZ<1PR$GDDY%1_N?&[P(TIY\C[(3E]V_#[
M-GRZN.&2[$@4X(\I$QELN*EBV!H5NYZA R8("F5 R_N[AT?U:WM=62;KA'DL
M8<"XTANX$>=2U31G<( -*.=:U0QXT,=2&O0'(>=V^6]^PI%EB?&4QRF%+BK+
M?13C7PXZFT,:#Y/\6RZVJC,,+)#B,1@X[XCEW&7^+:#\NQ>P!.438C=*N[W&
MEV5BN=IX9_[3<N\#@&],Y]] &B19#32-'3XI+(#(DN?M+LLNIDEOJ3HOF7^?
M#U)9 M0<JA=@K"RP\0HP^X+C%S1VC[+Q0RPMMIE)B7X089]QA:@J&H-L>Q30
MS*^*@O!_I;S>SH=T0 "CG*0"K8O/12<77=U>97$<DIS"4$Z<97$?^A]DT']&
MG)#-:SAQ LO";AR&9)"RZOS#]ER0%0(?YXVV01_, I>$F(3!:53-XL'EU,M"
M,?T,@)31>?^SXG)>5,GH]3+3*)O"[<5"6;PHJ^1])_,*,PC*Q:HH<-J0P^%C
M"7CF\O)F ) &&4KC,*#H3R'_LSTKAX54Q6N% T)I$)U6!23F0US.H9*#XW:
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MB),,;<V_,Y*$L+(,L7,>=4GR8D;?5='CS*/;[(OG6^F3>DDI@*T//?J43"8
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MDM8:NS2V9ZS;/V3WW\\.XL:P/^,7HQ]02P,$%     @ 4$2C4HFA5#Z* 0
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M-@BN743ODCS.']\*H3_3Y>=4SY_F_XEOSU,A9[Y$/BJF@BA$>L;H*1>P2'C
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MSX@F8S2LGA@=QL"$^Y:OEW"TV+]9/!/O+!TXVKO_H7OI'M8_VOL?4$L#!!0
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M02<Y_O+]AEQ= 9!!E*&F+@;>O22)A@GHA@@D<F3EJ^%C&-GU(-9P^-\*88&
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M   1              "  0    !D;FQI+3(P,C$P-3 S+FAT;5!+ 0(4 Q0
M   ( %!$HU*#:=3)C@(  )4)   1              "  <D5  !D;FQI+3(P
M,C$P-3 S+GAS9%!+ 0(4 Q0    ( %!$HU*)H50^B@$  -H"   5
M      "  888  !D;FQI+3(P,C$P-3 S7V-A;"YX;6Q02P$"% ,4    " !0
M1*-2!\](ZPT"  !_!@  %0              @ %#&@  9&YL:2TR,#(Q,#4P
M,U]D968N>&UL4$L! A0#%     @ 4$2C4I]:(5X]"@  HET  !4
M     ( !@QP  &1N;&DM,C R,3 U,#-?;&%B+GAM;%!+ 0(4 Q0    ( %!$
MHU)9.1%7M08  'HQ   5              "  ?,F  !D;FQI+3(P,C$P-3 S
M7W!R92YX;6Q02P$"% ,4    " !01*-2,L#EG&4@  "<;@$ &P
M    @ ';+0  97@Y.3%P<F5S<W)E;&5A<V5Q,3(P,C$N:'1M4$L%!@     '
-  < TP$  'E.      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
